1
项与 CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床试验A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ Myeloid Dendritic Cells in NSCLC Subtitle v3.0: A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells in Solid Tumors.
A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
100 项与 CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床结果
100 项与 CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel) 相关的转化医学
100 项与 CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel) 相关的专利(医药)
100 项与 CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel) 相关的药物交易